Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B.
Clinical Infectious Diseases 41(8): 1186-1195
2005
ISSN/ISBN: 1058-4838 Document Number: 260624
Document emailed within 1 workday
Related Documents
Galegov, G.A. 2007: Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS Antibiotiki i Khimioterapiia 52(1-2): 42-45Kuschak, D.; Mauss, S.; Schmutz, G.; Gantke, B. 2001: Simultaneous Determination of the New HIV Protease Inhibitor Lopinavir (ABT 378) and of Indinavir (1), Amprenavir, Saquinavir, Ritonavir (ABT 538) (2) and Nelfinavir (3) in Human Plasma by Gradient HPLC Clinical Laboratory 47(9-10): 471-477
Gianotti, N.; Poli, A.; Galli, M.; Pan, A.; Rizzardini, G.; Soria, A.; Viale, P.; Di Biagio, A.; Quirino, T.; Viganò, P.; Bonfanti, P.; d'Arminio Monforte, A.; Fortino, I.; Lazzarin, A. 2014: Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study New Microbiologica 37(4): 439-448
Chu, C-Jen.; Wang, Y-Jen.; Hwang, S-Jang.; Lu, R-Hwa.; Chang, F-Young.; Chang, C-Yu.; Yang, Y-Chun.; Lee, S-Dong. 2007: Kinetics of hepatitis C virus RNA load during pegylated interferon plus ribavirin therapy in Treatment-naive Chinese patients Hepato-Gastroenterology 54(75): 866-870
Saves, M.; Raffi, F.; Clevenbergh, P.; Marchou, B.; Waldner-Combernoux, A.; Morlat, P.; LeMoing, V.; Riviere, C.; Chene, G.; Leport, C.; The APROCOStudy Group, 2000: Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients Antimicrobial Agents and Chemotherapy 44(12): 3451-3455
Matthews, G.V.; Avihingsanon, A.; Lewin, S.R.; Amin, J.; Rerknimitr, R.; Petcharapirat, P.; Marks, P.; Sasadeusz, J.; Cooper, D.A.; Bowden, S.; Locarnini, S.; Ruxrungtham, K.; Dore, G.J. 2008: A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand Hepatology 48(4): 1062-1069
Macías, J.; Mira, J.é A.; López-Cortés, L.F.; Santos, I.; Girón-González, J.é A.; González-Serrano, M.; Merino, D.; Hernández-Quero, J.é; Rivero, A.; Merchante, N.ás.; Trastoy, M.ón.; Carrillo-Gómez, R.; Arizcorreta-Yarza, A.; Gómez-Mateos, J.ús.; Pineda, J.A. 2006: Antiretroviral therapy based on protease inhibitors as a protective factor against liver fibrosis progression in patients with chronic hepatitis C Antiviral Therapy 11(7): 839-846
Mathez, D.; Bagnarelli, P.; Gorin, I.; Katlama, C.; Pialoux, G.; Saimot, G.; Tubiana, P.; De Truchis, P.; Chauvin, J.P.; Mills, R.; Rode, R.; Clementi, M.; Leibowitch, J. 1997: Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy Antiviral Therapy 2(3): 175-183
Simpson, K.N.; Baran, R.W.; Kirbach, S.E.; Dietz, B. 2011: Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 14(8): 1048-1054
Roux, P.; Fugon, L.; Winnock, M.; Salmon-Céron, D.; Lacombe, K.; Sogni, P.; Spire, B.; Dabis, F.ço.; Carrieri, M.P. 2012: Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users Addiction 107(1): 152-159
Chong, K.T.; Pagano, P.J. 1997: In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates Antimicrobial Agents and ChemoTherapy 41(11): 2367-2373
Hoffmann, F.; Funk, M.; Linde, R.; Notheis, G.; Petropoulou, T.; Eberle, J.; Gürtler, L.; Belohradsky, B.H.; Wintergerst, U. 2002: Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection European Journal of Medical Research 7(7): 330-334
Patel, A.K.; Patel, K.K.; Naik, E.; Jingyi Duan; Ranjan, R.; Patel, J.K.; Salihu, H.M. 2011: Comparison of the Effectiveness of Low-Dose Indinavir/Ritonavir (IDV/r)- versus Atazanavir/Ritonavir (ATV/r)-Based Generic Antiretroviral Therapy in NNRTI-Experienced HIV-1-Infected Patients in India Journal of the International Association of Physicians in Aids Care 10(2): 111-118
Vieira, C.S.; Bahamondes, M.V.; de Souza, R.M.; Brito, M.B.; Rocha Prandini, T.R.; Amaral, E.; Bahamondes, L.; Duarte, G.; Quintana, S.M.; Scaranari, C.; Ferriani, R.A. 2014: Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women Journal of Acquired Immune Deficiency Syndromes 66(4): 378-385
Gutiérrez, Félix.; Padilla, S.; Masiá, M.; Navarro, Aés.; Gallego, J.; Hernández, I.; Ramos, Jé.Manuel.; Martin-Hidalgo, A. 2004: Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations Antiviral Therapy 9(1): 105-113
Saitta, C.; Pontisso, P.; Brunetto, M.R.; Fargion, S.; Gaeta, G.B.; Niro, G.A.; Picciotto, A.; Smedile, A.; Squadrito, G.; Raimondo, G. 2006: Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy Antiviral Therapy 11(7): 931-934
2000: Ritonavir/Saqinavir: dual protease inhibitor combination. Salvage therapy MMW Fortschritte der Medizin 142(3 Suppl): 41
Arystanbekova, M.; Balmasova, I.; Malova, E.; Sepiashvili, R. 2017: Antiretroviral Therapy and the Risk of Liver Fibrosis Progression in Hiv/Hcv Coinfected Patients Georgian Medical News 266: 58-63
Koudriakova, T.; Iatsimirskaia, E.; Utkin, I.; Gangl, E.; Vouros, P.; Storozhuk, E.; Orza, D.; Marinina, J.; Gerber, N. 1998: Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir Drug Metabolism and Disposition: the Biological Fate of Chemicals 26(6): 552-561
Waters, L.J.; Moyle, G.; Bonora, S.; D'Avolio, A.; Else, L.; Mandalia, S.; Pozniak, A.; Nelson, M.; Gazzard, B.; Back, D.; Boffito, M. 2007: Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients Antiviral Therapy 12(5): 825-830